
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics, Preclinical Pharmacology |
Departments of 1 Medicine, 2 Pharmacology, and 3 Biomedical Engineering, Columbia University, New York, New York; 4 Altana Pharma AG, Konstanz, Germany; and 5 Johns Hopkins University, School of Public Health, Baltimore, Maryland
ABSTRACT
Purpose: G3139 is an antisense bcl-2 phosphorothioate oligodeoxyribonucleotide that is currently being evaluated in Phase III clinical trials in several human cancers. The aim of the present work was to further identify the apparent non-bcl-2-dependent mechanism of this action of this compound in PC3 prostate cancer cells.
Experimental Design: We performed Affymetrix U95A oligonucleotide microarray studies on mRNA isolated from cells treated with G3139 and related oligonucleotides.
Results: Hierarchical clustering revealed the presence of a set of genes of which the expression was elevated on both 1 and 3 days after oligonucleotide treatment. Significantly, the persistence of expression of the up-regulation of these genes, many of which are members of the IFN cascade, was greater for G3139 than for any other oligomer evaluated. Furthermore, many of the genes with the greatest up-regulation of expression are also those of which the expression is up-regulated after treatment of cells with IFNs. Treatment of PC3 cells with either IFN-ß or -
recapitulated some of the aspects of the molecular and phenotypic changes observed after treatment with a G3139/Lipofectin complex. These include down-regulation of bcl-2 protein expression itself, down-regulation of protein kinase C
protein expression (but not that of other protein kinase C isoforms), alteration in p21/Waf1/Cip1 protein expression, up-regulation of MHC-I cell surface expression, and profound suppression of cell growth in the absence of a notable increase in cellular apoptosis. However, G3139 (when complexed with Lipofectin) did not induce the up-regulation of expression of either type I or type II IFNs, nor could IFNs be found in conditioned media from treated cells.
Conclusions: Oligonucleotide microarray experiments demonstrated that G3139 could induce elements of the IFN cascade in PC3 cells in vitro. In addition, the cellular phenotype obtained after treatment with exogenous IFN could, at least in part, recapitulate that obtained after G3139 treatment. Nevertheless, the oligonucleotide microarray experiments we performed also demonstrated that there are extremely large qualitative and quantitative differences between the two treatments.
This article has been cited by other articles:
![]() |
B. Larrivee, C. Freitas, M. Trombe, X. Lv, B. DeLafarge, L. Yuan, K. Bouvree, C. Breant, R. Del Toro, N. Brechot, et al. Activation of the UNC5B receptor by Netrin-1 inhibits sprouting angiogenesis Genes & Dev., October 1, 2007; 21(19): 2433 - 2447. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. Mocanu, K. W. Yip, J. Skliarenko, W. Shi, P. Busson, K.-W. Lo, C. Bastianutto, and F.-F. Liu Imaging and Modulating Antisense Microdistribution in Solid Human Xenograft Tumor Models Clin. Cancer Res., October 1, 2007; 13(19): 5935 - 5941. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Benimetskaya, K. Ayyanar, N. Kornblum, D. Castanotto, J. Rossi, S. Wu, J. Lai, B. D. Brown, N. Popova, P. Miller, et al. Bcl-2 Protein in 518A2 Melanoma Cells In vivo and In vitro. Clin. Cancer Res., August 15, 2006; 12(16): 4940 - 4948. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. C. Lai, W. Tan, L. Benimetskaya, P. Miller, M. Colombini, and C. A. Stein A pharmacologic target of G3139 in melanoma cells may be the mitochondrial VDAC PNAS, May 9, 2006; 103(19): 7494 - 7499. [Abstract] [Full Text] [PDF] |
||||
![]() |
D.-T. Chen, J. J. Chen, and S.-j. Soong Probe rank approaches for gene selection in oligonucleotide arrays with a small number of replicates Bioinformatics, June 15, 2005; 21(12): 2861 - 2866. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. C. Lai, L. Benimetskaya, A. Khvorova, S. Wu, E. Hua, P. Miller, and C.A. Stein Phosphorothioate oligodeoxynucleotides and G3139 induce apoptosis in 518A2 melanoma cells Mol. Cancer Ther., February 1, 2005; 4(2): 305 - 315. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Benimetskaya, J. C. Lai, A. Khvorova, S. Wu, E. Hua, P. Miller, L.-M. Zhang, and C. A. Stein Relative Bcl-2 Independence of Drug-Induced Cytotoxicity and Resistance in 518A2 Melanoma Cells Clin. Cancer Res., December 15, 2004; 10(24): 8371 - 8379. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Hu, G. Bebb, S. Tan, R. Ng, H. Yan, J. R. Sartor, L. D. Mayer, and M. B. Bally Antitumor Efficacy of Oblimersen Bcl-2 Antisense Oligonucleotide Alone and in Combination with Vinorelbine in Xenograft Models of Human Non-Small Cell Lung Cancer Clin. Cancer Res., November 15, 2004; 10(22): 7662 - 7670. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |